A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years

Clinical Breast Cancer

Volumn 17, Issue 7, 2017, Pages 516-525.e6

  Lourenco, Ana P ^a   Benson, Kasey L ^b   Henderson, Meredith C ^b   Silver, Michael ^b   Letsios, Elias ^b   Tran, Quynh ^b   Gordon, Kelly J ^b   Borman, Sherri ^b   Corn, Christa ^b   Mulpuri, Rao ^b   Smith, Wendy ^a   Alpers, Josie ^c   Costantini, Carrie ^d   Rohatgi, Nitin ^e   Yang, Rebecca ^f   Haythem, Ali ^g   Biren, Shah ^g   Morris, Michael ^h   Kass, Fred ⁱ   Reese, David E ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b Provista Diagnostics Inc   (United States)

^c Avera Health   (United States)

^d SCRIPPS RESEARCH   (United States)

^e Sutter Institute for Medical Research   (United States)

^f Lahey Clinic Medical Center North Shore   (United States)

^g HENRY FORD HOSPITAL   (United States)

^h Banner University   (United States)

ⁱ Sansum Clinic   (United States)

Author keywords

Biopsies; Imaging; Liquid biopsy; Serum proteins; Tumor associated autoantibodies

Indexed keywords

BIOLOGICAL MARKER; PROTEOME; TUMOR MARKER;

ADULT; ARTICLE; BENIGN BREAST TUMOR; BLOOD SAMPLING; BREAST CANCER; BREAST CARCINOMA; BREAST HYPERPLASIA; CANCER DIAGNOSIS; CONTROLLED STUDY; DIGITAL BREAST TOMOSYNTHESIS; ECHOGRAPHY; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; LIQUID BIOPSY; LOBULAR CARCINOMA IN SITU; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDICAL HISTORY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PREVALENCE; PROSPECTIVE STUDY; PROTEOMICS; SENSITIVITY AND SPECIFICITY; BLOOD; BREAST TUMOR; CARCINOMA IN SITU; DIAGNOSTIC IMAGING; LOBULAR CARCINOMA; MIDDLE AGED; MULTIMODAL IMAGING; PROCEDURES; PROGNOSIS;

ADULT; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAMMOGRAPHY; MIDDLE AGED; MULTIMODAL IMAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTEOME; PROTEOMICS;

EID: 85020666388     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2017.05.004     Document Type: Article

References (39)

1. Cancer Facts & Figures, 2015, 2015, American Cancer Society, Atlanta.
2. Breast Cancer Facts & Figures, 2011-2012, 2011, American Cancer Society, Atlanta.
3. Hollingsworth, A., Reese, D., Potential use of biomarkers to augment clinical decisions for the early detection of breast cancer. Oncol Hematol Rev 10 (2014), 103–109.
4. Bevers, T.B., Anderson, B.O., Bonaccio, E., et al., National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 7 (2009), 1060–1096.
5. Boyd, N.F., Guo, H., Martin, L.J., et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 356 (2007), 227–236.
6. Carney, P.A., Miglioretti, D.L., Yankaskas, B.C., et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138 (2003), 168–175.
7. van Breest Smallenburg, V., Duijm, L.E., Voogd, A.C., Jansen, F.H., Louwman, M.W., Mammographic changes resulting from benign breast surgery impair breast cancer detection at screening mammography. Eur J Cancer 48 (2012), 2097–2103.
8. Wang, A.T., Vachon, C.M., Brandt, K.R., Ghosh, K., Breast density and breast cancer risk: a practical review. Mayo Clin Proc 89 (2014), 548–557.
9. Pace, L.E., Keating, N.L., A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA 311 (2014), 1327–1335.
10. Bleyer, A., Welch, H.G., Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367 (2012), 1998–2005.
11. Cole, K., Tabernero, M., Anderson, K.S., Biologic characteristics of premalignant breast disease. Cancer Biomark 9 (2010), 177–192.
12. Campbell, J.B., Breast cancer-race, ethnicity, and survival: a literature review. Breast Cancer Res Treat 74 (2002), 187–192.
13. Kim, S.A., Chang, J.M., Cho, N., Yi, A., Moon, W.K., Characterization of breast lesions: comparison of digital breast tomosynthesis and ultrasonography. Korean J Radiol 16 (2015), 229–238.
14. Knuttel, F.M., Menezes, G.L., van den Bosch, M.A., Gilhuijs, K.G., Peters, N.H., Current clinical indications for magnetic resonance imaging of the breast. J Surg Oncol 110 (2014), 26–31.
15. Berg, W.A., Zhang, Z., Lehrer, D., et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 307 (2012), 1394–1404.
16. Berg, W.A., Tailored supplemental screening for breast cancer: what now and what next?. AJR Am J Roentgenol 192 (2009), 390–399.
17. Lei, J., Yang, P., Zhang, L., Wang, Y., Yang, K., Diagnostic accuracy of digital breast tomosynthesis versus digital mammography for benign and malignant lesions in breasts: a meta-analysis. Eur Radiol 24 (2014), 595–602.
18. Saving Women's Lives: Strategies for Improving Breast Cancer Detection and Diagnosis, 2005, The National Academies Press, Washington, DC.
19. Moazzezy, N., Farahany, T.Z., Oloomi, M., Bouzari, S., Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev 15 (2014), 1685–1688.
20. Dehqanzada, Z.A., Storrer, C.E., Hueman, M.T., et al. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol Rep 17 (2007), 687–694.
21. Lyon, D.E., McCain, N.L., Walter, J., Schubert, C., Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 57 (2008), 51–58.
22. Rykala, J., Przybylowska, K., Majsterek, I., et al. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol Oncol Res 17 (2011), 809–817.
23. Anderson, K.S., Sibani, S., Wallstrom, G., et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 10 (2011), 85–96.
24. Benoy, I.H., Salgado, R., Van Dam, P., et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10 (2004), 7157–7162.
25. Kovacs, E., Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed Pharmacother 55 (2001), 391–396.
26. Kovacs, E., The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed Pharmacother 55 (2001), 111–116.
27. Heer, K., Kumar, H., Read, J.R., Fox, J.N., Monson, J.R., Kerin, M.J., Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 7 (2001), 3491–3494.
28. Harris, L., Fritsche, H., Mennel, R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25 (2007), 5287–5312.
29. Fuzery, A.K., Levin, J., Chan, M.M., Chan, D.W., Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics, 10, 2013, 13.
30. Lacombe, J., Mange, A., Solassol, J., Use of autoantibodies to detect the onset of breast cancer. J Immunol Res, 2014, 2014, 574981.
31. Yahalom, G., Weiss, D., Novikov, I., et al. An antibody-based blood test utilizing a panel of biomarkers as a new method for improved breast cancer diagnosis. Biomark Cancer 5 (2013), 71–80.
32. Kruse, N., Schulz-Schaeffer, W.J., Schlossmacher, M.G., Mollenhauer, B., Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of alpha-synuclein and other proteins in cerebrospinal fluid. Methods 56 (2012), 514–518.
33. Anderson, K.S., Cramer, D.W., Sibani, S., et al. Autoantibody signature for the serologic detection of ovarian cancer. J Proteome Res 14 (2015), 578–586.
34. Henderson, M.C., Hollingsworth, A.B., Gordon, K., et al. Integration of serum protein biomarker and tumor associated autoantibody expression data increases the ability of a blood-based proteomic assay to identify breast cancer. PLoS One, 11, 2016, e0157692.
35. Jesneck, J.L., Mukherjee, S., Yurkovetsky, Z., et al. Do serum biomarkers really measure breast cancer?. BMC Cancer, 9, 2009, 164.
36. Friedman, J., Hastie, T., Tibshirani, R., Additive logistic regression: a statistical view of boosting. Ann Statist 28 (2000), 337–407.
37. Dettling, M., Buhlmann, P., Boosting for tumor classification with gene expression data. Bioinformatics 19 (2003), 1061–1069.
38. Soussi, T., p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60 (2000), 1777–1788.
39. Sickles, E., D'Orsi, C.J., Bassett, L.W., et al. ACR BI-RADS® Mammography. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System, 2013, American College of Radiology, Reston, VA.